Skip to main content
Premium Trial:

Request an Annual Quote

SensiGen to Use Sequenom Tools to Develop Assays That the Firms Will Co-Market

NEW YORK (GenomeWeb News) — SensiGen today said it will use Sequenom’s MassArray platform and QGE gene-expression tools to continue to develop several disease assays that the companies will co-market to reference labs for an indefinite period.
 
The first of SensiGen’s AttoSense tests to be developed on the Sequenom platform will be an assay for human papillomavirus. The company plans to submit that test to the US Food and Drug Administration by 2009.
 
SensiGen plans to develop three other tests, including assays for chronic kidney disease, inflammatory bowel disease, and lupus.
 
The companies said the AttoSense assay method can detect DNA from viruses, bacteria, blood, urine, and tissue.
 
Financial terms of the agreement were not released.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.